Page 6 - Jay Mei News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jay mei. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jay Mei Today - Breaking & Trending Today

Antengene to Host Research and Development Day on November 15th and 17th, 2022

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to. ....

Hong Kong , South Korea , Jay Mei , Asia Pacific , Peter Qian , Company Annual , Antengene Corporation , Hong Kong Stock Exchange , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Virtual English Session , Mandarin Session , Corporation Limited , Hybrid Mandarin Session , Eastern Time , Beijing Time , Chinese Session , Investor Relations , Patients Beyond , Greater China , Annual Report , Hong Kong Stock , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals ,

Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting

/PRNewswire/ At the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston, Massachusetts. ....

Bin Jiang , Shan Bo , Bo Shan , Hong Kong , United States , Peng Chen , South Korea , Jay Mei , Wenhui Yu , Peter Qian , Asia Pacific , Bing Hou , Ya Kong , Society For Immunotherapy Of Cancer Annual Meeting , Company Annual , Antengene Corporation , Hong Kong Stock Exchange , Antengene Corporation Limited , Cancer Annual Meeting , Eastern Time , Linjie Tian , Corporation Limited , Patients Beyond , Greater China , Annual Report , Hong Kong Stock ,

Antengene Announces XPOVIO Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma

XPOVIO (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in tripleclass refractory R/R MM. XPOVIO is the first of a new class of SINE medicines to be made available to Australian patients with penta-refractory R/R MM on the Pharmaceutical Benefits Scheme (PBS). SHANGHAI and HONG KONG, Sept. 1, 2022 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that XPOVIO (selinexor) in combination with dexamethasone (Xd) has been PBS Listed for the treatment of adult patients with R/R MM who have received at least four prior lines of therapy and whose disease is refra ....

Hong Kong , South Korea , Andrew Spencer , Jay Mei , Asia Pacific , Peter Qian , Karyopharm Therapeutics Inc , Company Annual , Antengene Corporation , Hong Kong Stock Exchange , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Therapeutic Goods Administration , Pharmaceutical Benefits Scheme , Corporation Limited , Professor Andrew Spencer , Alfred Hospital , Hayley Beer , Myeloma Australia , Tamara Etto , Senior Medical Director , Karyopharm Therapeutics , Patients Beyond , Greater China , Annual Report , Hong Kong Stock ,

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to. ....

United States , Hong Kong , South Korea , Jay Mei , Asia Pacific , Peter Qian , Company Annual , Antengene Corporation , American Society Of Clinical Oncology , International Myeloma Working Group , European Society Of Medical Oncology , Discovery Program , European Hematology Association , Celularity Inc , Bristol Myers Squibb , National Comprehensive Cancer Network , Chinese Society Of Clinical Oncology , Karyopharm Therapeutics Inc , Beigene Ltd , Hong Kong Stock Exchange , Biologics Drug Discovery Laboratory , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Business Development , Mainland China , Corporation Limited ,

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

ATG-018, a global rights asset developed by Antengene's internal R&D team, is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 monotherapy in patients with advanced tumors and hematologic malignancies. SHANGHAI and HONG KONG, Aug. 16, 2022 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announcedthat the first patient has been dosed in the Phase I ATRIUM trial to evaluate ATG-018 as a monotherapy in patients with advanced solid tumors and hematologic malignancies in Australia. The ATRIUM trial is a Phase I multi-center, open-label, dose f ....

United States , Hong Kong , South Korea , Jay Mei , Asia Pacific , Peter Qian , American Association For Cancer Research , Company Annual , Antengene Corporation , Hong Kong Stock Exchange , Antengene Corporation Limited , Rd Team At Antengene , Icon Medical Oncology Research Committee , Medical Oncology Research Committee , Associate Professor , Queensland School , Cancer Research , Annual Meeting , Corporation Limited , Patients Beyond , Greater China , Annual Report , Hong Kong Stock , Atg 018 , A Global Rights Asset Developed By Antengene 39s Internalr Ampd Team , S An Orally Bioavailable ,